• U.S. drug reviewers will ask an advisory panel if they should wait for more data before deciding whether to approve GPC Biotech proposed prostate cancer pill, a summary released Friday said.

  • Boston Scientific Misses View as Stent Sales Slide Friday, 20 Jul 2007 | 10:30 AM ET
    Boston Scientific Corp.

    Boston Scientific posted a lower-than-expected quarterly profit Friday as sales of its flagship drug-eluting heart stents fell by 32%.

  • Swedish drug company Meda said on Friday it signed an $800 million cash-and-stock deal to buy allergy and pain treatment specialist MedPointe. from a group of U.S. investors.

  • Pfizer Proposes Pay-for-Performance Thursday, 19 Jul 2007 | 3:41 PM ET

    Pfizer's "pay-for-performance" policy -- which essentially amounts to a money-back guarantee to pharmaceutical users and healthcare payers -- will be a boon for pharmaceutical companies, Catherine Arnold, director at Credit Suisse, said on "Power Lunch."

  • Pfizer's Kindler: Having to Explain The Lipitor Slip Thursday, 19 Jul 2007 | 2:25 PM ET
    Jeff Kindler

    Pfizer Chairman and CEO Jeff Kindler had some explaining to do on the company's earnings conference call this afternoon. He started by telling analysts, investors and reporters who were listening in (everyone's in a listen-only mode, only the analysts are allowed to ask questions), "Let me be direct. It was a tough quarter."

  • Glaxo Wins Positive Opinion on Drug Thursday, 19 Jul 2007 | 10:33 AM ET

    GlaxoSmithKline said that its cervical cancer vaccine Cervarix received a positive opinion from the European Committee for Human Medicinal Products and will now be proposed for final approval by the European Commission.

  • Roche Holding said Thursday its CEO will step down next March as the pharmaceutical company separates that job from the chairman's position. It also posted a 24% increase in first-half net profit.

  • Wyeth Beats Profit Forecast; Raises 2007 Outlook Thursday, 19 Jul 2007 | 7:54 AM ET

    Wyeth reported higher-than-expected second-quarter earnings Thursday on strong sales growth of its prescription drugs, and it raised its profit forecast for the year.

  • Pfizer Profit Falls Unexpectedly; Lipitor Sales Decline Wednesday, 18 Jul 2007 | 3:43 PM ET

    Pfizer Wednesday reported lower-than-expected quarterly earnings on competition with generics, and said global sales of cholesterol fighter Lipitor fell 13% amid slipping demand for the company's flagship product.

  • Pfizer And Lipitor: Prescription For Big Loss Wednesday, 18 Jul 2007 | 11:19 AM ET

    Yesterday, I blogged that you should watch the Lipitor number in Pfizer's earnings report today. Well, the world's biggest drug company, is having major problems with the world's biggest-selling drug. Lipitor sales fell a surprising 25% in the U.S. and 13% worldwide in the second quarter. And the company says for the full year revenue from the cholesterol fighter could be down as much as 5%.

  • Abbott Profit Rises as Humira, Other Drugs Shine Wednesday, 18 Jul 2007 | 9:36 AM ET

    Abbott Laboratories posted higher second-quarter earnings Wednesday on increased sales of its prescription drugs, with global revenue from arthritis treatment Humira jumping 50%.

  • Novartis cut its full-year results outlook as generic competition pressured sales of a key blood-pressure drug, and said U.S. regulators had delayed the approval process for an important cancer treatment.

  • JNJ: Not Doing Okay As Investors Check-Up On Stock Tuesday, 17 Jul 2007 | 11:26 AM ET

    The headline might say, "Johnson & Johnson Beats the Street," but investors are looking behind it and that's what is pushing this Dow component down this morning. For example, JNJ says its topline growth would have been just 3.6% instead of 13% if it had not bought Pfizer's consumer health care business last year for $16.6 billion. JNJ is kind of a three-pronged hybrid: pharma, medical devices and consumer healthcare.

  • These days, it's not uncommon to see campaigns calling for the withdrawal of a drug from the market because of safety concerns. That's why this campaign urging the approval of a drug is extraordinary. Proponents of Dendreon's Provenge took out this no-frills, half-page ad in the opinion section of Sunday's edition of "The Washington Post".

  • Merger news and corporate announcements were some of the catalysts behind the most actively traded stocks on Thursday.

  • ImClone Lung Cancer Drug Erbitux Fails Trial Thursday, 12 Jul 2007 | 8:07 AM ET

    ImClone Systems said on Thursday its drug Erbitux failed to meet the main goal in a late-stage study for advanced lung cancer.

  • ImClone: Out to Prove Dr. Deuel's Bona Fides Wednesday, 11 Jul 2007 | 2:20 PM ET

    A couple of months ago I took ImClone to task here for putting a Hollywood studio executive on its Board of Directors. The post caused me to be frozen out of communication with the company--calls were not returned, emails did not get a reply. We've since mended fences and it looks like IMCL may have gotten a message. Here's part of its press release issued late yesterday announcing that Dr. Thomas Deuel is coming onto the Board.

  • Dendreon's Provenge: Soap Opera Drama Over SEC Probe? Wednesday, 11 Jul 2007 | 10:22 AM ET

    While I'm sitting in a plane on the tarmac at Newark Liberty Airport for going on four hours now I write about the latest twist and turn in the Dendreon saga. Late Tuesday, in an SEC filing, the company disclosed that it got a letter dated July 9th informing Dendreon that the agency has launched an informal inquiry "related to the Company’s clinical trials for Provenge .

  • European Stocks to Watch: Banco Popular Milano Wednesday, 11 Jul 2007 | 7:32 AM ET

    European banking stocks were among the hardest hit in a global selloff Wednesday as investors feared U.S. subprime weakness could spread to European mortgage lenders.

  • With a big drug finishing its Phase III trial, this stock could be ready to move.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.